David Smith - Aligos Therapeutics Executive Operations
| ALGS Stock | USD 11.75 0.99 9.20% |
Executive
David Smith is Executive Operations of Aligos Therapeutics
| Phone | 800 466 6059 |
| Web | https://www.aligos.com |
David Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Smith against Aligos Therapeutics stock is an integral part of due diligence when investing in Aligos Therapeutics. David Smith insider activity provides valuable insight into whether Aligos Therapeutics is net buyers or sellers over its current business cycle. Note, Aligos Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aligos Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Smith over two weeks ago Acquisition by David Smith of 10500 shares of Gran Tierra at 4.29 subject to Rule 16b-3 | ||
David Smith over two weeks ago Acquisition by David Smith of 53126 shares of Sinclair Broadcast at 13.7275 subject to Rule 16b-3 | ||
David Smith over a month ago Disposition of 14635 shares by David Smith of Sonic Automotive at 72.97 subject to Rule 16b-3 | ||
David Smith over a month ago Disposition of 8323 shares by David Smith of Sonic Automotive at 72.97 subject to Rule 16b-3 |
Aligos Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5029) % which means that it has lost $0.5029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1584) %, meaning that it created substantial loss on money invested by shareholders. Aligos Therapeutics' management efficiency ratios could be used to measure how well Aligos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Moses Makunje | Nuvation Bio | 45 | |
| Lee Stern | Achilles Therapeutics PLC | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Thomas Rollins | Assembly Biosciences | 69 | |
| Danielle OlanderMoghadassian | CytomX Therapeutics | N/A | |
| Colleen Sjogren | Nuvation Bio | 55 | |
| Udayan MD | NextCure | N/A | |
| Sebastien Maloveste | NextCure | N/A | |
| Philippe Sauvage | Nuvation Bio | 48 | |
| Amy CFA | Assembly Biosciences | N/A | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Anuj MD | Assembly Biosciences | 47 | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| YuWaye MD | CytomX Therapeutics | 57 | |
| Kevin Shaw | NextCure | 50 | |
| Steven CPA | NextCure | 62 | |
| Shannon Ryan | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -4.16 | ||||
| Return On Asset | -0.5 |
Aligos Therapeutics Leadership Team
Elected by the shareholders, the Aligos Therapeutics' board of directors comprises two types of representatives: Aligos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aligos. The board's role is to monitor Aligos Therapeutics' management team and ensure that shareholders' interests are well served. Aligos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aligos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leonid Beigelman, Pres Director | ||
| Dr MBA, President CEO | ||
| Lucinda JD, Chief VP | ||
| TseI Lin, VP Head | ||
| Matthew MD, Executive Officer | ||
| Dr DABT, Executive Sciences | ||
| Kristina Engeseth, Ex Culture | ||
| Kristina MBA, VP Culture | ||
| John Fry, Ex Devel | ||
| Lesley CPA, Executive CFO | ||
| Hardean MD, Executive Officer | ||
| Julian DPHIL, Executive Officer | ||
| David Smith, Executive Operations |
Aligos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aligos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.16 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (32.69) % | ||||
| Current Valuation | 22.85 M | ||||
| Shares Outstanding | 5.31 M | ||||
| Shares Owned By Insiders | 11.58 % | ||||
| Shares Owned By Institutions | 34.03 % | ||||
| Number Of Shares Shorted | 712.99 K | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 16.68 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.